Chemomab Therapeutics Ltd.

AI-generated fair value estimate for this company.

Method: Going-concern-adjusted net cash value: $6.69M net cash ($0.92/share on 7.25M shares) haircut to 60% given a cash runway of well under 12 months against an ~$8.7M annual burn rate (implying near-certain dilutive financing), plus a $0.30/share risk-adjusted option value for the nebokitug (CM-101) program in primary sclerosing cholangitis following positive 48-week Phase 2 data and FDA fast-track designation.

Reasoning: Chemomab is a clinical-stage biotech with a very short cash runway, so intrinsic value is driven primarily by near-term dilution risk against net cash, with a modest add-on for its one differentiated, fast-tracked rare-disease asset; a standard revenue/FCF DCF is not meaningful pre-approval and pre-revenue.